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INTRODUCTION
Von Hippel Lindau (VHL) disease is an autosomal domi-
nant disease that produces a variety of tumors and cysts in the
central nervous system (CNS) and visceral organs (1). Tumor
types seen in VHL include hemangioblastoma in the CNS
and retina, renal cell carcinoma (RCC), pheochromocytoma,
and pancreatic neuroendocrine tumors. VHL is associated
with the inactivation of a tumor suppressor gene located on
chromosome 3p25-26 (2).
The global prevalence of patients with VHL has been report-
ed to be between 1 in 30,000 and 1 in 100,000 (3). Howev-
er, VHL is very rare in Korea; there are only three reports of
patients with VHL and RCC (4-6). In this report, we exam-
ine Korean patients with VHL to characterize the types of
benign and malignant tumors that develop and the clinical
characteristics of concomitant RCC.
MATERIALS AND METHODS
Patients
Between January 1996 and July 2008, 24 patients were
diagnosed with VHL and 1,514 patients were diagnosed with
RCC in our institute. In patients with VHL, we examined
clinical manifestations and accompanying lesions including
CNS hemangioblastoma, retinal angioma, RCC, renal cyst,
pancreatic tumor, pancreatic cyst, pheochromocytoma, and
epididymal cyst. These conditions were diagnosed as follows.
Retinal angiomas were diagnosed by ophthalmoscope in the
department of ophthalmology, pancreatic lesions were diag-
nosed by computed tomography (CT) or ultrasonography
(US), CNS hemangioblastomas and pheochromocytomas were
diagnosed by CT and magnetic resonance imaging (MRI),
and renal cysts and RCCs were diagnosed by CT or US and
their size, characteristics and metastasis were evaluated by
CT. Genetic testing was performed in the department of clin-
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Clinical Characteristics of Renal Cell Carcinoma in Korean Patients
with von Hippel-Lindau Disease Compared to Sporadic Bilateral or
Multifocal Renal Cell Carcinoma
This study was done to analyze the clinical characteristics of renal cell carcinoma
(RCC) in Korean patients with von Hippel-Lindau (VHL) disease. Between January
1996 and July 2008, 1,514 patients were diagnosed with RCC and 24 patients were
diagnosed with VHL disease at our institute. We analyzed the clinical characteris-
tics of the 24 patients diagnosed with VHL. The mean age of patients with VHL was
39.2±12.6 yr; the mean age of patients with both VHL and RCC was 42.5±10.3
yr. Among the 24 patients with VHL, 7 patients had retinal angiomas, 11 had RCC,
16 had renal lesions, 18 had pancreatic lesions and 21 had cerebellar hemangioblas-
tomas. There was no significant difference between survival rates of patients with
VHL alone and those with VHL and RCC. However, cancer-specific survival rates
were significantly different between patients with both VHL and RCC and patients
with sporadic bilateral or multifocal RCC. In our Korean study, the incidence of RCC
in patients with VHL disease is 45.8% and the incidence of VHL disease in patients
with RCC is 0.73%. Due to the low overall incidence of VHL in Korea, extended multi-
institutional studies are needed to establish the true characteristics of VHL disease. 
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ical genetics. The diagnostic criteria for VHL include the fol-
lowing: 1) one CNS hemangioblastoma and visceral manifes-
tations of VHL, or 2) any manifestation and possession of a
known VHL gene or a family history of VHL. 
Data analysis
We studied patients diagnosed with RCC during the same
time period in our institute and compared this information
with the incidence of RCC in Korean patients with VHL.
In patients with RCC related to VHL disease, we examined
age, clinical characteristics of the tumor, symptoms, metas-
tasis, type of pathology, and survival. We also documented
the management of patients with RCC, which included par-
tial nephrectomy, radical nephrectomy, immunotherapy, and
target therapy.
We examined mean age, histological type, pathologic tumor
grade and mean size of sporadic bilateral or multifocal RCC
and compared the survival rates of 11 VHL patients with RCC
to those of 54 patients with sporadic bilateral RCC or spo-
radic multifocal RCC. 
Survival rates of patients with VHL with and without RCC,
and VHL patients with RCC and patients with sporadic bilat-
eral or multifocal RCC were analyzed using the Kaplan-Meier
log-rank test. A value of P<0.05 was considered statistically
significant. Analyses were performed using SPSS 12.0 soft-
ware (SPSS, Inc. Chicago, IL, U.S.A.).
RESULTS
Incidence 
Between January 1996 and July 2008, 1,514 patients were
diagnosed with RCC, 24 patients were diagnosed with VHL,
and 11 patients were diagnosed with both RCC and VHL
in our institute. In Korean patients, the incidence of RCC
in patients with VHL is 45.8% and the incidence of VHL
in patients with RCC is 0.73%. 
Clinical manifestations of VHL disease
The mean age at diagnosis was 39.2±12.6 yr for VHL. In
these patients, the distribution of tumor manifestations was as
follows: 5 had pheochromocytomas, 7 (29.1%) had retinal an-
giomas, 16 (66.7%) had renal cysts or RCCs, 18 (75.0%) had
pancreatic cysts or tumors, and 21 (87.5%) had hemangioblas-
tomas of the cerebellum or spinal cord (Table 1). One pheo-
chromocytoma patient had hypertension while three had normal
blood pressure. No patient had diabetes mellitus (DM), includ-
ing those with pancreatic islet cell tumors and pancreatic cysts. 
Cerebellar or 
spinal
hemangioblastoma
Adrenal
mass
Renal
cyst
RCC
Retinal
angioma
Pancreatic 
cyst or mass
SexAge (yr)No. Family Hx.
1 42 M + - + + - + -
2 22 F - - + + - - -
3 29 M - + - + - - -
4 47 F - - - + - - -
5 47 M - - + + - + +
6 54 F - + - + - - -
7 18 M + - + + - - -
8 43 M - - - + - + -
9 33 M - - + + - - +
10 65 M - - + + - + +
11 49 F + - + + + + +
12 42 M - - + + - + +
13 27 F - + + - - + +
14 22 M - - + + - - -
15 60 F - - + + - + -
16 34 M - - + + - - +
17 36 M - - + + - + +
18 51 M + + + + + - -
19 29 M - + - - + - -
20 50 M - + - + + + +
21 21 M + - + - + + -
22 43 F - + + + - + +
23 42 M - - + + - - +
24 34 F - - + + - + -
Table 1. Profiles of 24 patients with von Hippel-Lindau disease
No., number; Hx., history; RCC, renal cell carcinoma; M, male; F, female.
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VHL gene analysis
We performed genetic testing on 12 patients for VHL gene
mutations. Of them, 7 patients had mutations (Table 2). Two
patients with mutations were mother and son. Twelve patients
did not undergo genetic testing. 
Clinical characteristics of RCC in VHL disease
Of the 24 patients with VHL, 16 had renal lesions: 11
(45.8%) had RCC and 5 had renal cysts without RCC. Thus
in this study, the incidence of VHL disease in patients with
RCC was 0.73% (11 patients). The mean age of VHL pati-
ents with RCC was 42.5±10.3 yr. The tumor characteris-
tics were as follows: five patients had unilateral RCCs and six
had bilateral RCCs; nine patients had multiple RCCs; the
largest tumor was 8-9 cm and the smallest was 1.8 cm; symp-
toms included one patient with flank pain and one with gross
hematuria; nine patients were asymptomatic; two patients
had lung metastasis, and one had brain metastasis. 
Management
Of the 11 patients who received treatment, 3 underwent
radical nephrectomies, 1 received target therapy with sorafenib
after a radical nephrectomy, 2 underwent partial nephrecto-
mies, 2 received IL-2 immunotherapy, and 1 with lung metas-
tases received target therapy with sunitinib. The stage of the
two patients who underwent partial nephrectomies was pT1a.
The stages of the four patients who underwent radical nephrec-
tomy and target therapy after a radical nephrectomy were 2
pT2, 1 pT1b and 1 pT1a with multiple RCCs. Two patients
received no treatment due to severe complications associat-
ed with cerebellar hemangioblastomas. 
Pathology of RCC
Three patients who received immunotherapy or target ther-
apy underwent needle biopsies and six patients underwent
surgery. All nine patients who underwent biopsies were shown
to have conventional RCC pathology (Table 3). Pathologic
tumor grade was 1 in 1 patient, 2 in 5 patients and 3 in 3
patients. 
Characteristics of sporadic bilateral or multifocal RCC
We analyzed 54 patients with sporadic bilateral or multi-
focal RCC. 17 patients were sporadic bilateral RCC and 37
patients were sporadic multifocal RCC. The mean tumor size
of sporadic bilateral or multifocal RCC was 6.59±3.34 cm.
Histology types in these patients were conventional RCC in
47 patients, papillary RCC in 4 patients and chromophobe
RCC in 3 patients. Pathologic tumor grades in these patients
were 1 in 4 patients, 2 in 21 patients, 3 in 19 patients, 4 in
6 patients and unknown in 4 patients. 
Follow-up and prognosis
The mean follow-up period of patients with VHL was 37.3
±7.5 months. At follow-up, 7 of 24 patients with VHL had
T, thymine; C, cytosine; A, adenine; G, guanine; His, histidine; Gln, glu-
tamine; Arg, arginine; Trp, tryptophan; Asn, asparagine; Ser, serine.
No. VHL gene
1 3 bp deletion (TCT, codon 76-77) (7) 
2 His115Gln (CAC>CAA) (8)
3 Arg167Gln (50DSUB G>A) (9)
4 Trp88Arg (262T>C) (10)
5 Arg167Trp (499C>T) (9)
6 Trp88Arg (TGG>CGG) (10)
7 Asn78Ser (8)
Table 2. Mutations of the von Hippel-Lindau (VHL) gene
Case
No.
Age (yr) Site
Max. diam-
eter (cm) 
Single or
multiple
Pathology Symptom
Distant
metastasis
Survival
RCC
stage
Treatment
1 47 B 2.7 Multiple No No cT1acN0cM0 Refuse - -
2 33 R 8 Multiple C No pT2pN0cM0 Nephrec - +
3 65 B 8 Multiple C GH pT2pN0cM0 Nephrec+ + +
Sorafenib
4 49 B 9 Multiple C FP cT2cN1cM1 Sunitinib - +
5 42 R 2 Single C No pT1acN0cM0 Partial - +
6 27 L 3 Single C No pT1acN0cM0 Partial - +
7 34 B 5.1 Multiple No No pT1bcN0cM0 Observ - +
8 36 L 1.8 Multiple C No pT1acN0cM0 Nephrec - +
9 50 B 4.3 Multiple C No cT1bcN0cM0 IL-2 - +
10 43 B 3.5 Multiple C No cT1acN0cM0 IL-2 - +
11 42 R 6.5 Multiple C No cT1bcN0cM0 Nephrec - +
Table 3. Description of renal cell carcinoma in nine patients with von Hippel-Lindau disease
B, bilateral; R, right; L, left; C, conventional renal cell carcinoma; RCC, renal cell carcinoma; GH, gross hematuria; FP, flank pain; Nephrec, nephrecto-
my; Partial, partial nephrectomy; Observ, observation only; IL-2, IL-2 based immunotherapy.
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died and 2 VHL patients with RCC had died, one from com-
plications of a cerebellar hemangioblastoma and one from
lung and brain metastases. There was no significant differ-
ence in overall survival rates between patients with VHL with
and without RCC (P=0.195) (Fig. 1). However, the cancer-
specific survival rate was significantly different between VHL
with RCC and sporadic bilateral or multifocal RCC (P<0.05)
(Fig. 2). 
DISCUSSION
The global prevalence of patients with VHL disease has
been reported to be between 1 in 30,000 and 1 in 100,000
(3, 11, 12). It has been reported that 40-70% of patients with
VHL have concomitant RCC and that the mean age of pati-
ents diagnosed with both disorders is 37 yr old (13). This is
the first report that analyzes the clinical characteristics of
RCC in a group of Korean patients with VHL. In this study,
45.8% of patients with VHL had concurrent RCC and their
mean age was 42.5±10.3 yr old. 
Renal cysts commonly occur in VHL disease and can give
rise to RCC (13). In this study, a total of 13 patients had renal
cysts and 5 patients had renal cysts without RCC. If the lat-
ter were followed-up, RCC may have developed. For this rea-
son, serial imaging is important to detect malignant trans-
formation of benign cysts.
Before modern screening tests were established, many pa-
tients with VHL died before reaching 50 yr of age, mostly
due to complications of CNS hemangioblastoma or RCC
(14, 15). Today, modern diagnostic and treatment techniques
allow earlier detection and improved prognosis. For exam-
ple, retinal angiomas can lead to retinal detachment and blind-
ness, but if detected early these lesions respond well to laser
photocoagulation or cryotherapy (13).
Early detection of RCCs enables kidney-preserving rather
than radical nephrectomy. RCCs in VHL disease grow slow-
ly, usually less than 0.3 cm per year (16, 17). Therefore, after
diagnosis, follow-up CTs are indicated. If the tumor is larg-
er than 3 cm, nephron-sparing surgery (NSS) is performed
to preserve renal function (18-20). NSS is effective and safe
in patients with VHL disease and renal function is preserved
without increasing the risk of metastasis (21). In this study,
two patients with RCC smaller than 3 cm underwent par-
tial nephrectomies and there was no recurrence or metasta-
sis during follow-up. 
Compared with its sporadic counterpart, RCC in VHL is
associated with a less aggressive course, demonstrating slow-
er growth, a lower rate of metastasis, and most importantly,
improved cancer-specific survival (17). In this study, there
was no significant difference in survival rates between VHL
patients with and without RCC. Of the VHL patients with
RCC, one died of RCC during follow-up and six died from
complications of CNS hemangioblastomas. This implies that
careful management of complications of CNS hemangioblas-
toma in Korean patients with VHL may improve survival.
Furthermore, cancer-specific survival of VHL patients with
RCC was significantly better than that of patients with spo-
radic bilateral or multifocal RCC. 
Given that the diagnostic criteria for VHL disease include
any disease manifestation and a family history or known VHL
gene, over 50% of VHL patients have only one manifestation
(11, 15). One limitation of this retrospective study is failure
to enroll patients with only one manifestation with a family
history of VHL disease or with a positive genetic test. VHL
genetic testing and asking family history was not performed
on patients with only one manifestation of VHL disease. 
In conclusion, the results of this study show that in a Korean
population, 0.73% of patients with RCC have associated
VHL disease and 45.8% of patients with VHL disease have
concomitant RCC. However, due to the relatively small study
size and the fact that VHL disease is rare in Korea, further
Fig. 1. Overall disease-specific survival rates for patients with von
Hippel-Lindau (VHL) disease only, and VHL with and without renal
cell carcinoma (RCC).
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Fig. 2. Cancer-specific survival rates of patients with both von Hip-
pel-Lindau (VHL) disease and RCC, versus patients with sporadic
bilateral or multifocal RCC.
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multi-institutional studies are needed to establish the char-
acteristics of VHL disease in Korea. 
REFERENCES
1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan
WM, Oldfield EH. von Hippel-Lindau disease. Lancet 2003; 361:
2059-67.
2. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse
T, Kuzmin I, Modi W, Geil L. Identification of the von Hippel-Lin-
dau disease tumour suppressor gene. Science 1993; 260: 1317-20.
3. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R,
Sampson J, Williams A, Ferguson-Smith MA, Morton N. Von Hip-
pel-Lindau disease: a genetic study. J Med Genet 1991; 28: 443-7.
4. Kim DS, Kim JJ, Yoon DK, Koh SK, Won NH. A case of von Hip-
pel-Lindau disease diagnosed by initial symptoms of urologic mani-
festation. Korean J Urol 1987; 28: 126-32.
5. Kang IS, Lee YI, Seo IY, Jeong HJ, Rim JS. Renal cell carcinoma
associated with von Hippel-Lindau disease treated by wedge resec-
tion. Korean J Urol 2004; 45: 495-7.
6. Kim JH, Cheon SH, Oh CS, Kim YM, Park RJ. Cystic renal cell car-
cinoma associated with von Hippel-Lindau disease treated by nephron
sparing surgery. Korean J Urol 2005; 46: 93-5.
7. Klein B, Weirich G, Brauch H. DHPLC-based germline mutation
screening in the analysis of the VHL tumor suppressor gene: useful-
ness and limitations. Hum Genet 2001; 108: 376-84.
8. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR,
Orcutt ML, Duh FM, Glenn G, Hsia YE, Lamiell J, Li H, Wei MH,
Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM,
Lerman M, Zbar B. Germline mutations in the von Hippel-Lindau
disease tumor suppressor gene: correlations with phenotype. Hum
Mutat 1995; 5: 66-75.
9. Richards FM, Webster AR, McMahon R. Woodward ER, Rose S,
Maher ER. Molecular genetic analysis of von Hippel-Lindau disease.
J Intern Med 1998; 243: 527-33.
10. Rocha JC, Silva RL, Mendonca BB, Marui S, Simpson AJ, Camargo
AA. High frequency of novel germline mutations in the VHL gene
in the heterogeneous population of Brazil. J Med Genet 2003; 40:
e31.
11. Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lin-
dau syndrome: evidence for a complex genetic locus. Lancet 1991;
337: 1052-4.
12. Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne
SJ, Whitehouse R, Dodd C, Lavin M, Hartley N, Super M, Evans
DG. A genetic register for von Hippel-Lindau disease. J Med Genet
1996; 33: 120-7.
13. Friedrich CA. Von Hippel-Lindau syndrome. A pleomorphic condi-
tion. Cancer 1999; 86 (Suppl 2): 2478-82.
14. Richard S, Campello C, Taillandier L, Parker F, Resche F. Haeman-
gioblastoma of the central nervous system in von Hippel-Lindau dis-
ease. French VHL study Group. J Intern Med 1998; 243: 547-53.
15. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT,
Ferguson-Smith MA. Clinical features and natural history of von
Hippel-Lindau disease. Q J Med 1990; 77: 1151-63.
16. Hes FJ, Slootweg PJ, van Vroonhoven TJ, Hene RJ, Feldberg MA,
Zewald RA, Ploos van Amstel JK, Hoppener JW, Pearson PL, Lips
CJ. Management of renal cell carcinoma in von Hippel-Lindau dis-
ease. Eur J Clin Invest 1999; 29: 68-75. 
17. Neumann HP, Bender BU, Berger DP, Laubenberger J, Schultze-see-
mann W, Wetterauer U, Ferstl FJ, Herbst EW, Schwarzkopf G, Hes
FJ, Lips CJ, Lamiell JM, Masek O, Riegler P, Mueller B, Glavac D,
Brauch H. Prevalence, morphology and biology of renal cell carci-
noma in von Hippel-Lindau disease compared to sporadic renal cell
carcinoma. J Urol 1998; 160: 1248-54.
18. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours
in patients on chronic haemodialysis. Histopathology 1993; 22: 135-9.
19. Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund
G, Skinner DG, Esriq D, Richie JP, deKernion JB, Marshall F, Marsh
CL. Treatment of renal cell carcinoma in von Hippel-Lindau disease:
a multicenter study. J Urol 1995; 153: 1812-6.
20. Walther MM, Choyke PL, Weiss G, Manolatos C, Long J, Reiter R,
Alexander RB, Linehan WM. Parenchymal sparing surgery in patients
with hereditary renal cell carcinoma. J Urol 1995; 153: 913-6.
21. Ploussard G, Droupy S, Ferlicot S, Ples R, Rocher L, Richard S, Benoit
G. Local recurrence after nephron-sparing surgery in von Hippel-
Lindau disease. Urology 2007; 70: 435-9.
